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Background: Multiple myeloma is characterized by clonal expansion of B cells producing monoclonal
immunoglobulins or fragments thereof, which can be detected in the serum and/or urine and are ideal target
antigens for patient-specific immunotherapies.
Methods: Using phage particles as immunological carriers, we employed a novel chemically linked idiotype vaccine
in a clinical phase I/II trial including 15 patients with advanced multiple myeloma. Vaccines composed of purified
paraproteins linked to phage were manufactured successfully for each patient. Patients received six intradermal
immunizations with phage idiotype vaccines in three different dose groups.
Results: Phage idiotype was well tolerated by all study participants. A subset of patients (80% in the middle dose
group) displayed a clinical response indicated by decrease or stabilization of paraprotein levels. Patients exhibiting
a clinical response to phage vaccines also raised idiotype-specific immunoglobulins. Induction of a cellular immune
response was demonstrated by a cytotoxicity assay and delayed type hypersensitivity tests.
Conclusion: We present a simple, time- and cost-efficient phage idiotype vaccination strategy, which represents
a safe and feasible patient-specific therapy for patients with advanced multiple myeloma and produced promising
anti-tumor activity in a subset of patients.
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ParaproteinBackground
Due to the prospect of effective tumor therapies with
minimal adverse events, anti-tumor vaccines have long
been investigated. A successful example is the passive
vaccination against B cell lymphoma with the anti-CD20
antibody rituximab [1]. However, rituximab targets
CD20 expressed not only on lymphoma cells but normal
B cells as well. A personalized active vaccination strategy
targeting a tumor-specific antigen may accomplish an
even better and more sustained therapeutic response.
An easily identifiable tumor-specific antigen, from
which a patient-specific vaccine could be generated, is
the variable region of the clonal immunoglobulin (idio-
type, Id) expressed on the surface of B cell cancers,* Correspondence: fuat.oduncu@med.uni-muenchen.de
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article, unless otherwise stated.being unique to each neoplastic B cell clone. However,
provoking sufficient immunogenicity of the Id, which
represents a tumor-specific antigen [2], but nevertheless
is a self-protein, is a still unmet challenge. Previously, Id
was usually coupled to a strong immunogenic carrier
protein, such as keyhole limpet hemocyanin (KLH), and
co-administered with immunostimulatory adjuvants,
such as granulocyte-monocyte colony stimulating factor
(GM-CSF) [3,4]. Despite encouraging preclinical results,
Id-based immunotherapy so far has given disappointing
outcomes in patients; i.e. clinical phase III studies aimed
at obtaining regulatory approval for Id-KLH vaccines
failed to reach their primary endpoints [5,6]. Utilizing
the immunogenic properties of the filamentous phage,
we previously demonstrated a superior immunogenicity
of a chemically linked Id-phage compared to Id-KLH
and a genetically engineered Id-phage in the preclinical
setting [7]. We here examine the therapeutic feasibilitytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tients with advanced multiple myeloma (MM).
Methods
Multiple myeloma Id purification
Paraproteins were purified from serum and urine sam-
ples according to their heavy-chain isotype and subclass
employing protein A affinity chromatography followed
by ion exchange chromatography on an ÄKTA Purifier
10 using Unicorn 4.11 software (Amersham Biosciences,
Braunschweig, Germany) as described previously [7].
Briefly, serum (500 μl) was passed through 0.8 μm and
0.2 μm nitrocellulose filters equilibrated with 500 μl 20
mM tetra-sodium diphosphate buffer (pH 6.4; Merck,
Darmstadt, Germany) and bound to a HiTrap Protein A
HP/5 ml column (Amersham Biosciences). Individual
IgG fractions were eluted using a pH step gradient (100
mM sodium citrate/150 mM NaCl/pH 3.5; Merck), dia-
lyzed against 20 mM Tris/HCl/pH 8.5 and bound to
HiTrap Q-HP/5 ml column (Amersham Biosciences)
equilibrated with 20 mM Tris/HCl/pH 8.5 (Merck,
Darmstadt, Germany). Samples were eluted with 20 mM
Tris/1 M NaCl/pH 8.5 (Merck) using a linear salt gradi-
ent and the paraprotein was dialyzed against phosphate-
buffered saline (PBS; Invitrogen, Karlsruhe, Germany).
The purified paraprotein was sterile filtered through a
0.2 μm nitrocellulose.
Preparation of Id vaccines
The preparation of bacteriophages (M13K07, Amersham
Biosciences) at large scale was performed as described
previously [7]. Contaminating endotoxins were removed
by two-phase Triton X-114 separation as described else-
where [8,9], resulting in an endotoxin concentration of
< 1 unit/ml [7]. Chemically linked Id-phage was gener-
ated as described [7] by coupling purified paraproteins
to bacteriophages (50 mg/ml in PBS) with 0.1% (v/v)
glutaraldehyde/water and an Id protein/phage ratio of
1:10 (w/w). Phage vaccines were sterile filtered and filled
according to the work-flow by the pharmacy of the
Klinikum Innenstadt (Ludwig-Maximilians-Universität,
Munich). Sterility tests were performed according to
standard procedures by the Max von Pettenkofer-
Institut (Ludwig-Maximilians-Universität, Munich).
Safety and toxicity
Preclinical toxicity studies were performed in cooper-
ation with an independent partner (Bioservice Scientific
Laboratories GmbH, Planegg, Germany) in compliance
with the principles of Good Laboratory Practice. A wild-
type phage dosage of 10 ml/kg (rat, n = 6) and 50 ml/kg
body weight (mouse, n = 6) intraperitoneally and sub-
cutaneously resulted in no clinical signs of toxicity
throughout the observation period of 14 days. In NewZealand white rabbits, intradermal and intramuscular
application (0.2 ml) provoked a slight acute reactionary
inflammatory heterophil cell response with moderate
hemorrhage detected in all rabbits (n = 14), lacking ne-
crosis or ulceration. Overall, histopathological responses
at the injection site were slight, suggesting that signifi-
cant toxicity would not occur in humans at this dosage.
Enzyme-linked immunosorbent assay (ELISA)
ELISA analyses were performed as described [7]. Detec-
tion antibodies (goat-anti-human IgG/IgG1/IgG2/IgG3/
IgG4) were purchased from Southern Biotech, Birming-
ham, USA.
Study design and participants
The clinical study was designed as a phase I/II trial pri-
marily addressing the feasibility and safety of phage Id
vaccinations in MM patients. The local Institutional Re-
view Board of the University of Munich approved the
study. This study was announced to the Paul-Ehrlich-
Institut (Langen, Germany) according to paragraph 40,
section 1, no. 6 AMG and the Government of Upper
Bavaria (Regierung Oberbayern, Germany) according to
paragraph 67, section 1, no. 6 AMG (Study-No.: MKI-
TR02/2002). All participants gave written informed con-
sent. Seventeen patients > 18 years of age suffering from
a terminal stage of MM (as defined by partial response
or relapsed disease more than three months after high
dose melphalan chemotherapy (at a dose between 140
and 200 mg/m2) and autologous stem cell transplant-
ation) were recruited within one year. Patients had
all undergone one or two high dose chemotherapies
followed by autologous stem cell transplantation. Fur-
ther treatment included lenalidomide, bendamustine,
cyclophosphamide, thalidomide or bortezomib. All pa-
tients had been treated with corticosteroids. Patients
received no chemotherapy, steroids or other myeloma-
related drugs three months prior to study enrolment.
Criteria for relapse were a M gradient < 2 g/dl that pro-
gressed less than 0.2 g/dl per month or an increase
of urine light chain excretion > 100 mg/24 hours within
one month. Further inclusion criteria were at least
one positive Multitest-Immigon test (Biosyn, Fellbach,
Germany), general condition according to Eastern Co-
operative Oncology Group performance status score < 2
(Karnowsky index ≥ 70%) and written informed consent.
Exclusion criteria were active infections or auto-
immune diseases, intake of thalidomide, lenalidomide,
interferon alpha, dexamethasone, hydrocortisone or
other immunosuppressive or non-approved drugs within
6 weeks prior to study inclusion; MM stage II or III ac-
cording to Salmon & Durie requiring therapy, extrame-
dullar myeloma, leukocyte count < 2,500/μl, CD45+ cell
count < 1200/μl, CD3+ cells < 700/μl, CD4+ cells < 500/μl,
Table 1 Baseline characteristics of the study participants
No. Gender Age Myeloma isotype Vaccination dose level
1 M 62 λ-light chain 0.25 mg
2 M 58 IgA1-κ/light chain 0.25 mg
3 M 56 IgG1-λ 0.25 mg
4 F 69 IgG1-λ 0.25 mg
5 F 59 IgG1-λ 0.25 mg
6 F 62 IgG1-κ 1.25 mg
7 F 50 IgG1-κ 1.25 mg
8 M 59 IgG1-κ 1.25 mg
9 M 57 IgG1-κ 1.25 mg
10 M 63 IgG1-λ 1.25 mg
11 M 52 IgG1-κ 2.5 mg
12 M 62 κ-light chain 2.5 mg
13 M 63 IgG1-κ 2.5 mg
14 F 60 IgG1-κ 2.5 mg
15 M 66 IgG1-κ 2.5 mg
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< 8 g/dl, heart failure, therapy-refractory hypertension,
therapy-refractory diabetes mellitus, chronic lung dis-
ease with a FeV1 < 50% or diffusion capacity < 50%, bili-
rubin > 2.0 mg/dl, liver transaminases > three times the
upper limit, glomerular filtration rate < 30 ml/min, pre-
vious organ transplantation other than autologous stem
cell transplantation, participation in another study, severe
mental disease or insufficient willingness to cooperate.
Two patients were excluded due to an infringement of the
eligibility criteria caused by active hepatitis and tumor-
related anemia.
Patient vaccination
Patients received a total of six intradermal immuniza-
tions with the phage-conjugated Id protein vaccine at
day 1, 7, 14 and week 4, 8 and 12. The vaccine dose was
0.25 mg for patients 1–5 and was subsequently escalated
to 1.25 mg for patients 6–10 and 2.5 mg for patients
11–15 as no serious adverse events were observed (equal
to 1 × 1011 – 2.5 × 1012 bacteriophages). Vaccine doses of
1 × 1010, 1 × 1011 and 5 × 1011 were previously tested
successfully in the murine BCL1 lymphoma model, with
the best anti-phage antibody response after application
of 5 × 1011 bacteriophages [7]. Each vaccine formulation
additionally contained 100 μg/m2 GM-CSF (Leukomax®,
Novartis) as adjuvant and 0.2 mg KLH (Immucothel®,
Biosyn Corporation, Carlsbad, CA, USA) as control
antigen. As cytokine adjuvant, 100 μg/m2 GM-CSF was
administered close to the vaccine injection site subcuta-
neously for three consecutive days after the vaccination. Fif-
teen patients were treated with at least three vaccinations.
Determination of cytotoxicity
Cytotoxic T lymphocyte (CTL) activity was determined
employing the single cell-based fluorogenic cytotoxicity
assay (CyToxiLux assay, OncoImmunin Inc, Gaithersburg,
USA). Freshly thawed peripheral blood mononuclear cells
(PBMCs), isolated by Ficoll-gradient centrifugation of hep-
arinized blood from MM patients obtained at different
times of vaccination, were used as effector cells. Bone
marrow cells obtained from the patient before vaccine
treatment were used as target cells. 1 ml of frozen bone
marrow target cells were rapidly thawed at 37°C, trans-
ferred to a reagent tube containing 9 ml of complete
RPMI, 10% (v/v) fetal calf serum, spun for 8 minutes at
1500 rpm, re-suspended in medium at 2 × 106/ml and in-
cubated with target cell marker at 1 μl/ml at 37°C for 1
hour, washed twice with a 10-fold volume of medium and
adjusted to 2 × 106 cells/ml. The effector PBMCs were
thawed and re-suspended (1 × 108/ml). Target cell suspen-
sion (100 μl) was dispensed with effector cells in effector-
target ratios of 50:1, 25:1, 12:1 and 5:1. Controls were
PBMCs and bone marrow cells alone adjusted withmedium to a final volume of 200 μl. After incubation for 2
hours at 37°C and 5% CO2, samples were subjected to cas-
pase substrate reaction for 30 minutes at 37°C. After
washing, the samples were analyzed by flow cytometry.
Delayed type hypersensitivity test
Phage Id vaccine, KLH, wild type phage and tumor Id
were injected intracutaneously at a dose of 20 μg each four
weeks after the last vaccination. The delayed type hyper-
sensitivity reaction was determined 48 hours after the
challenge by monitoring reddening, swelling and indur-
ation. An induration > 5 mm in diameter was considered
minor positive (“+”). An induration > 10 mm in diameter
was considered positive (“++”), an induration > 15 mm in
diameter was considered strongly positive (“+++”).
Skin biopsy
Patient 7 was chosen to undergo a skin biopsy of the site
of phage Id challenge, since this patient displayed a posi-
tive Id-related delayed type hypersensitivity reaction and
an Id-specific humoral response. Staining was performed
with hematoxylin-eosin and anti-CD8 (Dako GmbH,
Hamburg, Germany) and anti-CD4 (Novocastra, Berlin,
Germany) antibodies for immunohistochemistry analysis.
Results
Patient characteristics, toxicity and feasibility of phage Id
vaccine
The characteristics of the study participants are shown
in Table 1. All 15 vaccines were manufactured success-
fully within a mean production time of two weeks for
0.25 and 1.25 mg and three weeks for 2.5 mg vaccine
dosages. Phage vaccination was well tolerated with only
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tion at the vaccine injection site and flu-like symptoms.
All observed adverse events are summarized in Additional
file 1. There was no dose-limiting toxicity at the three
dose levels tested.
Clinical response of patients vaccinated with phage Id
vaccine
Clinical response was determined by serum M gradient
and 24-hour light chain excretion measurement in pa-
tients identified as numbers 1–5, 6–10 and 11–15 re-
ceiving 0.25, 1.25 and 2.5 mg dosages of vaccine per
treatment, respectively. The patients’ individual M gradi-
ent and 24-hour light chain excretion are displayed in
Figure 1 and Table 2. A decrease or stabilization of para-
protein levels and/or 24-hour light chain excretion wasFigure 1 Clinical response of patients vaccinated with Id-phage. Parap
individual patient.apparent during treatment course in 11 out of 15 patients
(patients 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14). After vaccination
with 0.25 mg phage Id vaccine, reductions of paraprotein
levels were mainly observed during the first three weekly
immunizations (patients 3–5), whereas in one patients
suffering from IgA MM and treated with 0.25 mg phage
vaccines containing light chains, the level of IgA parapro-
tein decreased 65% during treatment and follow up (pa-
tient 2). In contrast to the 0.25 mg-group, in which only
two patients (patients 2 and 4) had stable paraprotein
levels after three months, four of five patients having re-
ceived the 1.25 mg vaccine dose displayed stable or re-
duced paraprotein concentrations in this time range
(patients 7–10). In the 2.5 mg group, one patient showed
reduction of paraprotein levels after treatment initiation
and stable levels during follow up (patient 13), whereasrotein serum levels (black) and light chain excretion (gray) of each
Table 2 Paraprotein levels or 24-hour protein excretion in the urine before and after the vaccine treatment as well as
the lowest level during treatment (mg/dl)










1 1.57 3.43 8.19 3.43 -
2 0.51 0.64 0.36 0.36 0.30
3 1.57 3.43 4.01 3.30 5.75
4 1.17 1.26 1.11 0.99 1.23
5 0.54 1.07 1.86 1.03 2.27
6 1.10 1.46 1.91 1.20 2.45
7 1.61 1.99 1.78 1.45 2.12
8 0.55 0.43 0.58 0.34 0.57
9 1.51 1.66 1.46 1.20 1.46
10 1.68 1.79 1.42 1.22 1.66
11 0.89 1.35 2.43 1.20 1.88
12 2.84 3.54 3.99 3.54 5.40
13 1.90 1.65 1.67 1.29 1.81
14 1.17 1.46 1.81 1.17 2.34
15 1.07 1.40 1.90 1.33 -
Roehnisch et al. Journal of Translational Medicine 2014, 12:119 Page 5 of 11
http://www.translational-medicine.com/content/12/1/119another patient experienced reduction of paraprotein con-
centrations after the first three immunizations, followed
by a re-rise of paraprotein levels thereafter (patient 14).
The remaining patients in this high dose group (patients
11, 12 and 15) exhibited no clinical response to the phage
Id vaccination.
Figure 2 shows the best clinical response of all patients
(A) and the relative changes of paraprotein levels during
treatment and follow up in each treatment group (B).
Patients in the 1.25 mg group displayed the best re-
sponse with the greatest drop of paraprotein levels
during treatment and the lowest paraprotein levelsFigure 2 Paraprotein changes during treatment and follow up. (A) Ma
changes of paraproteins during treatment and follow up. (I) Maximum drop o
88 days in the 0.25 mg group (range 6–148 days), 18 days in the 1.25 mg gro
days). (II) Paraprotein levels immediately after the last vaccination in relation t
paraprotein levels three months after the last vaccination in comparison to paimmediately after and three months after the last vaccin-
ation in relation to paraprotein levels detected before
the first vaccination. However, these differences did not
reach statistical significance in the limited number of
study participants.
Humoral immune response of patients vaccinated with
phage Id vaccine
Anti-Id antibody levels and antibodies against the carrier
components KLH and phage were determined in patients
in the projected optimal 1.25 mg phage Id vaccine dosage
group (patients 6–10) over the time course of administrationximum absolute paraprotein decrease of each patient. (B) Percental
f paraprotein levels during treatment; median time after first vaccination:
up (range 7–78 days) and 22 days in the 2.5 mg group (range 20–120
o paraprotein levels immediately before the first vaccination. (III) Relative
raprotein levels immediately before treatment.
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phage vaccines (patients 7–10) also raised tumor Id
specific immunoglobulins. Antibody titers as high as
1:25,000 and 1:90,000 were found in patients 7 and 10,
respectively. In this treatment group, 4 of 5 patients had
a detectable anti-Id response. Patient 6 did not clinically
respond to treatment and developed no measurable Id-
specific humoral response (data not shown).
Both the Id-specific (Figure 3B) and phage-specific
(Figure 3C) antibodies mainly comprised the IgG-
isotype subtypes IgG1 and to a lesser amount IgG3,
whereas IgG2 and IgG4 were only detectable in small
amounts.
All treated patients demonstrated high levels of phage-
specific antibodies (data not shown). The phage-specific
antibody response was dose-dependent and detectable as
early as 2 weeks after the first phage vaccination. In con-
trast, KLH-specific antibodies were only detectable in
80% of the patients. Furthermore, KLH-specific antibody
levels were approximately ten times lower and only de-
tectable two weeks later than phage-specific antibodies.
Figure 3D shows the results of patient 2, having received
0.25 mg phage Id vaccination. The results are represen-
tative for study participants having received 0.25 and
1.25 mg phage Id vaccination. Regarding the immuno-
globulin subtypes, a similar pattern with a predominant
IgG1 response was observed in KLH-specific and phage-Figure 3 Anti-Id, anti-phage and anti-KLH-specific IgG responses. (A)
phage Id vaccine. Patients’ sera were obtained shortly before each vaccinat
antibodies. (B) Anti-Id specific immunoglobulin subtypes and anti-phage sp
immunization with 1.25 mg phage Id vaccine. The results are representativ
(patients 7–10). (D) Antibody response to KLH (left) and wild type phage (r
week 4, 8, 12). Results of patient 2, having received 0.25 mg phage Id vaccspecific antibodies as compared to Id-specific antibodies
(data not shown).
Cellular immune response of patients vaccinated with
phage Id vaccine
For measurement of cytotoxicity activity peripheral
blood mononuclear cells (PBMCs) were collected at day
1 or 4 weeks after the first vaccination of the 1.25 mg
phage vaccine dose from patient 7. These cells were used
as effector cells for comparison against bone marrow bi-
opsy samples containing MM target cells taken before
the first vaccination. Use of the CyToxiLux apoptosis de-
tection kit revealed that the PBMCs collected at 4 weeks
were able to kill target myeloma cells across all effector
to target cell ratios tested (Figure 4A), whereas PBMCs
obtained at day 0 exhibited a low cytotoxic activity. At
effector to target ratio 50:1, maximal lysis was 44% for
the 4 week phage vaccine-primed PBMCs versus only
11% for PBMCs isolated at day 1, demonstrating the
capacity of the phage idiotype vaccine to induce cyto-
toxic activity in a patient suffering from MM.
The patients’ cellular immune responses were further
examined by delayed type hypersensitivity (DTH) tests
against Id-phage, wildtype phage, myeloma Id protein
and KLH (Table 3). DTH response was determined 48
hours after application of the respective antigens. All
patients developed a strong DTH reaction against phageId-specific antibody response of patients 7–10 having received 1.25 mg
ion (day 1, 7, 14, 28, 56 and 84) and examined by ELISA using anti-Id
ecific immunoglobulin subtypes (C) in patient 7 at day 28 after
e for patients, who had raised and analyzed Id-specific antibodies
ight). Serum was taken shortly before each vaccination (day 1, 7, 14,
ination, are shown.
Figure 4 Cellular anti-tumor response. (A) Cytotoxic T lymphocyte (CTL) response in patient 7. Peripheral blood mononuclear cell cytotoxicity
was determined by flow cytometry analysis against bone marrow cells comprising MM cells using an apoptosis detection kit. Target cells were
taken from bone marrow biopsy samples from patient 7 before the first vaccination. PBMCs were collected 4 weeks after the first vaccination
with 1.25 mg phage Id vaccine. E:T: effector/target cell ratio. (B) Skin biopsy oft the site of phage Id challenge of patient 7. CD8+ (red), but no
CD4+ T cell infiltrate was demonstrated.
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by induration, redness and swelling at the site of chal-
lenge, whereas the reaction evoked against purified mye-
loma Id protein was weaker compared to the other
antigens. However, in two patients having received the
1.25 mg page vaccine dosage (patients 7 and 10), DTH
was unequivocally positive. Two more patients from the
1.25 mg-group displayed minor skin reactions indicating
a positive vaccine response (patients 8 and 9). In order
to characterize the type of infiltrating cells, a skin biopsy
was obtained from the site of the challenge of patient 7.
Immunohistochemical analysis revealed an infiltration of
neutrophils, macrophages and lymphocytes, the latter
representing CD8+ T cells (Figure 4B). In contrast, CD4+Table 3 Results of the delayed-type hypersensitivity test;
n.d. not done
No. Phage-idiotype vaccine KLH Wild type phage Idiotype
1 +++ +++ +++ -
2 +++ +++ +++ -
3 +++ +++ +++ -
4 +++ +++ +++ -
5 +++ +++ +++ -
6 +++ +++ +++ -
7 +++ +++ +++ +
8 +++ +++ +++ +
9 +++ +++ +++ +
10 +++ +++ +++ ++
11 +++ +++ +++ -
12 +++ +++ +++ -
13 +++ +++ +++ +
14 +++ +++ +++ +
15 n.d. n.d. n.d. n.d.T-cells and CD19+ B cells were not readily detectable as
part of the DTH response.
Discussion
The present phase I/II study is the first trial employing a
novel chemically linked phage-based Id vaccine targeting
MM. We demonstrate a fast method for generating
tumor-specific vaccinations with a maximal production
success rate. Endotoxins were efficiently removed from
phage preparations by an optimized purification protocol
[7,9,10] and the resulting phage vaccine compositions
could be readily employed in the vaccination studies.
Previous methods based on generating a hybridoma cell
line or PCR amplification of the Id from small numbers
of tumor cells are costly and have failure rates as high as
15% with long production times of 3 to 13 months to
vaccine completion [11,12].
We took advantage of the phage-inherent immuno-
genicity and the phage’s feature to allocate thousands of
well-defined sites available for chemical conjugation
[13]. The high molecular weight paraprotein was chem-
ically coupled to the phage surface at high density. Pre-
clinical exploration of the resulting phage vaccine
revealed a superior immunogenicity compared to KLH-
coupled Id and the genetically engineered phage express-
ing the Id on the major coat protein g8 [7]. In the
present study, the humoral response against phage was
raised earlier and more efficiently than against the well-
known KLH, which was used as control antigen. Thus,
although KLH-coupled Id still represents the gold stand-
ard for Id vaccinations and has been shown to provide
protection in the murine tumor challenge model [14,15],
chemically conjugated Id-phage may have the potential
of a superior immunogenicity.
So far, clinical trials employing active anti-Id vaccina-
tions were largely disappointing with mixed responses
[16]. Several phase I/II studies documented clinical response
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carrying the t(14;18) translocation in 8 out of 11 pa-
tients with minimal residual follicular lymphoma [3]. In
other studies, Id-KLH vaccines failed to elicit an anti-Id
immune response in more than half of the patients
[4,12,21]. In Id vaccine trials with myeloma patients
using Id-pulsed dendritic cells amongst others,
altogether about 55% of patients mounted an Id-specific
response and about 12% displayed a clinical response
[23,24]. Clinical response was difficult to evaluate in the
majority of studies, because vaccines were mostly con-
ducted in a state of minimal residual disease based on
the presumption derived from animal studies that vacci-
nations are more successful in a state of low tumor
burden, entailing that most patients had previously re-
ceived cytoreductive and immunosuppressive therapy
[16]. The present study was designed as clinical phase
I/II trial primarily serving to determine safety, toxicity
and initial response. As a consequence, patients allowed
to participate by the approval of the local ethics com-
mittee were patients with advanced disease suffering
from a relapse or partial remission after high dose
chemotherapy. Due to a high tumor load and subse-
quently impaired immune function in myeloma pa-
tients, for whom the bone marrow as the predominant
site of tumor growth progressively loses its ability to
procure a normal pool of immunological active cells,
these patients were not expected to respond to active
immunotherapy. Moreover, preclinical studies suggest
that high circulating paraprotein amounts are associated
with unresponsiveness to Id vaccination [25]. Neverthe-
less, treatment with the phage Id vaccine led to a clinical
response in several patients, reflected by a reduction or
stabilization of paraprotein levels. These effects were as-
sociated with the induction of anti-Id antibodies in 4 of
5 patients after vaccination with 1.25 mg phage vaccine,
whereas a further dose escalation to 2.5 mg did not in-
crease efficacy. The 2.5 mg dose group displayed a
weaker response than the 1.25 mg dose group, which we
rate as incidental finding due to the low patient number.
Remarkably, Id-specific antibodies were developed in
several patients despite the presence of high paraprotein
levels and despite the assumption that most of the
mounted anti-Id antibodies exist in patients’ sera in the
form of immune complexes bound to the serum para-
protein, emphasizing the superior immunogenicity of
the present phage vaccine formulation.
Besides the induction of Id-specific antibodies, cellular
immune response is of importance for an effective anti-
tumor response. In treatment-naive patients with indo-
lent B cell lymphoma, only cellular-mediated responses
correlated with superior progression-free survival and
durable objective remissions [26]. In MM patients, the
cellular immune response is especially crucial, sincemyeloma cells secrete their tumor-specific immunoglob-
ulins and thus the anti-Id humoral immune response
may result in binding and neutralizing of anti-Id specific
antibodies by soluble paraproteins [27]. Accordingly, it
was found previously that reduction of circulating mye-
loma cells correlated with vaccine-induced Id-specific T
cell responses [28]. Thus, it is fundamental that phages
are able to be incorporated by antigen-presenting cells
and to induce not only a humoral, but also a cellular im-
mune response [29,30]. Uptake and processing of the
phage-coupled Id protein and subsequent presentation
via both the MHC I and II is likely. Antibody subtype
analysis in the phage-vaccinated patients revealed that
detected anti-Id antibodies comprised mainly the sub-
type IgG1 and to a lesser extend IgG3, suggesting that a
Th1-like T cell response is elicited by phage Id vaccin-
ation, since it is known that IgG1 and IgG3 isotypes pro-
mote antibody-dependent cellular cytotoxicity and
complement-dependent cytotoxicity [31]. This is consist-
ent with the fact that interferon-γ, a cytokine produced
by Th1 cells, enhances IgG1 production in humans [32].
The positive anti-Id specific skin reaction of patients dis-
playing an anti-Id specific humoral response confirms
the induction of a cellular immune response. Immuno-
histochemical analysis of the DTH lesions revealed an
infiltration of neutrophils, macrophages and lympho-
cytes, which were mainly CD8+ T cells, indicating that
Id-conjugated phage vaccines generate an effective cyto-
toxic T cell response.
It is still impossible to determine in advance which pa-
tients will respond to the costly Id vaccines. Naturally,
response to treatment depends on the immune response
generated towards the Id [33] and thus it is not surpris-
ing that only patients developing antibodies against their
own Id have shown benefit with regard to time to pro-
gression and overall survival in previous clinical studies
[16,33,34]. Accordingly, we demonstrate a correlation of
clinical response and anti-Id humoral immune response.
Additionally, the phage vaccine dose seemed to play a
role for induction of Id-specific antibodies. Furthermore,
another study including patients with follicular lymph-
oma found that the vaccine isotype of the fragment
crystallizable region may affect immunogenicity, as IgM-
Id-KHL improved disease-free survival, whereas IgG-Id-
KLH vaccination had no effect [6]. An explanation for
the latter finding may be that the fragment crystallizable
region of IgG has highly promiscuous MHC class II T
cell epitopes specifically activating regulatory T cells and
thus skewing immune response towards tolerance rather
than immunogenicity [35]. However, neither perform-
ance scores nor response to chemotherapy or percentage
of T cell subsets in tumor biopsy specimens were valid
markers to distinguish patients with or without anti-Id
response. It is also unlikely that the Id-specific immune
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competency, because most patients mount a substantial
immune response to KLH [34], which was confirmed in
the present study.
While phage-specific antibodies were detectable in all
patients of the present study, only a subset of patients
developed anti-Id antibodies. Hence, Id immunogenicity
is still insufficient within this cohort of patients, which
was also reflected by a weaker skin reaction evoked by
purified myeloma Id protein in comparison to other an-
tigens. Further strategies to improve the Id immunogen-
icity are under investigation, but still have to prove
efficiency in the clinical setting. Phage may be further
optimized by design, for example by co-expression of
fragments or antigenic determinants promoting the up-
take of bacteriophages by dendritic cells [36]. On the
other hand, genetic removal or modification of immuno-
dominant regions of coat proteins was demonstrated to
focus and improve the epitope-specific immune response
by decreasing the antigen complexity of the phage
surface [37]. From a pathophysiological point of view,
strategies to overcome T cell tolerance by checkpoint
blockade inhibitors may be well suited for combination
with vaccinations. Cytotoxic T-lymphocyte antigen 4
(CTLA4) ligation is important for the immunosuppres-
sive function of regulatory T cells and anti-CTLA4 anti-
bodies produced encouraging results in melanoma
patients [38]. An alternative target is the PD-1/PD-L1
axis. PD-1 (programmed cell death protein 1) is expressed
by activated T cells and binds to its ligand PD-L1 that is
expressed on potential target cells, thereby rendering the
T cell unresponsive [39-41]. Expression of PD-1 and its li-
gands in the microenvironment of myeloma and recent
data indicating a role of the PD-1 pathway in the immune
evasion by myeloma cells make therapeutic PD-1/PD-L
inhibition an interesting option in multiple myeloma [42].
However, severe toxicities were reported after use of
checkpoint blockade inhibitors, including 23% grade 3 or
4 adverse effects, such as inflammatory colitis and hy-
pophysitis after use of anti-CTLA4 antibodies and car-
diomyopathy and lung infiltrations after application of
anti-PD-L1/PD-1 antibodies [38,43].
Conclusion
While refinements for increasing the immunogenicity of
the target Id may still be needed, we conclude from our
data that myeloma Id paraproteins chemically conju-
gated to phage particles appear to be suitable for use as
vaccines and capable of evoking tumor-specific immune
responses. The current study demonstrates the feasibility
to rapidly create tumor-specific phage vaccines for each
individual patient. The present data may be helpful and
encouraging for the design of larger clinical trials involv-
ing MM patients, preferably earlier in their diseasecourse, e.g. during first remission, when the immune
function is not yet severely impaired by extensive clonal
plasma cell proliferation and multiple chemotherapies
and thus a better response to active vaccination can be
expected.
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